Medication Description: Flumazenil (Flumazenil)
Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a] [1,4] benzodiazepine-3-carboxylate.
Synonym: Anexat, Anexate.
White or almost white crystalline powder. Insoluble in water, slightly soluble in acidic aqueous solutions.
Being a competitive blocker of benzodiazepine receptors, it eliminates the central psychomotor effects of benzodiazepine tranquilizers: neutralizes the hypnotic-sedative effect, promotes the restoration of respiration and consciousness during their overdose. At the same time, it has intrinsic agonistic activity in relation to benzodiazepine receptors and has an anticonvulsant effect.
Used to eliminate the central (except for anticonvulsant) effects of benzodiazepine tranquilizers (including when taken out of anesthesia, the differential diagnosis of their overdose).
Assign intravenously (in 5% glucose solution or 0.9% sodium chloride solution): in anesthetic practice - 0.0002 g (0.2 mg) for 15 s, if necessary, 0.0001 (0.1 mg) through 1 minute to a total dose of 0.001 g (1 mg); in intensive care - in the initial dose of 0.0003 g (0.3 mg); if necessary, repeat every 60 seconds to a total dose of 0.002 g (2 mg).
Possible side effects: flushing of the face, feeling of fear, palpitations (with quick administration), convulsions (with epilepsy in history), symptoms of benzodiazepine abstinence.
Product form: 0.01% solution for injection in ampoules of 5 and 10 ml.
Storage: List B.